Solanezumab: too late in mild Alzheimer's disease?

被引：43
|
作者：
不详
机构：
来源：
LANCET NEUROLOGY | 2017年 / 16卷 / 02期
关键词：
D O I：
10.1016/S1474-4422(16)30395-7
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：97 / 97
页数：1
相关论文
共 50 条
  • [21] Immunotherapies in Alzheimer’s disease: Too much, too little, too late or off-target?
    Isabelle St-Amour
    Francesca Cicchetti
    Frédéric Calon
    Acta Neuropathologica, 2016, 131 : 481 - 504
  • [22] Phase 3 Trials of Solanezumab and Bapineuzumab for Alzheimer's Disease REPLY
    Doody, Rachelle S.
    Farlow, Martin
    Aisen, Paul S.
    NEW ENGLAND JOURNAL OF MEDICINE, 2014, 370 (15): : 1460 - 1460
  • [23] Phase 3 Trials of Solanezumab for Mild-to-Moderate Alzheimer's Disease (vol 370, pg 311, 2014)
    Doody, R. S.
    NEW ENGLAND JOURNAL OF MEDICINE, 2014, 371 (06): : 584 - 584
  • [24] Alzheimer disease: are we intervening too late?
    Virginia Olga B. Emery
    Journal of Neural Transmission , 2011, 118 : 1361 - 1378
  • [25] Alzheimer disease: are we intervening too late?
    Emery, Virginia Olga B.
    JOURNAL OF NEURAL TRANSMISSION, 2011, 118 (09) : 1361 - 1378
  • [26] Delayed-Start Analyses in the Phase 3 Solanezumab EXPEDITION3 Study in Mild Alzheimer’s Disease
    Hong Liu-Seifert
    M. G. Case
    S. W. Andersen
    K. C. Holdridge
    P. S. Aisen
    S. Kollack-Walker
    E. Siemers
    The Journal of Prevention of Alzheimer's Disease, 2018, 5 : 8 - 14
  • [27] Efficacy and Safety of Intravenous Solanezumab in Patients with Mild to Moderate Alzheimer's Disease: Results of Two Phase 3 Studies
    Hake, Ann
    Siemers, Eric
    Carlson, Christopher
    Estergard, Wahiba
    Sundell, Karen
    Henley, David
    Eads, Jennifer
    Sexton, Cora
    Liu-Seifert, Hong
    Sethuraman, Gopalan
    Chen, Yun-Fei
    Dean, Robert
    Willis, Brian
    Demattos, Ronald
    Mohs, Richard
    NEUROLOGY, 2013, 80
  • [28] Alzheimer's Disease: Antibody Solanezumab has no Effect in the preclinical Stage
    Simon, Annika
    FORTSCHRITTE DER NEUROLOGIE PSYCHIATRIE, 2024, 92 (07/08) : 261 - 262
  • [29] Delayed-Start Analyses in the Phase 3 Solanezumab EXPEDITION3 Study in Mild Alzheimer's Disease
    Liu-Seifert, H.
    Case, M. G.
    Andersen, S. W.
    Holdridge, K. C.
    Aisen, P. S.
    Kollack-Walker, S.
    Siemers, E.
    JPAD-JOURNAL OF PREVENTION OF ALZHEIMERS DISEASE, 2018, 5 (01): : 8 - 14
  • [30] Efficacy and Safety of Intravenous Solanezumab in Patients with Mild to Moderate Alzheimer's Disease: Results of Two Phase 3 Studies
    Hake, Ann M.
    Siemers, Eric
    Carlson, Christopher
    Estergard, Wahiba
    Sundell, Karen
    Henley, David
    Eads, Jennifer
    Sexton, Cora
    Dean, Robert A.
    Willis, Brian
    DeMattos, Ronald
    Mohs, Richard
    AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY, 2013, 21 (03): : S138 - S138
12345